Short answer

CE marked medical software that complies with the EU MDR can be placed on the Great Britain market until 30 June 2030, and on 21 October 2026 the government announced that it intends to recognise EU MDR and IVDR CE marking indefinitely; that still needs legislation, planned before 30 June 2028. Either way, a manufacturer outside the UK needs a UK Responsible Person, MHRA registration before placing devices on the GB market, and compliance with the GB post-market surveillance requirements in force since 16 June 2025. UKCA marking under UK MDR 2002 remains the alternative route, and Northern Ireland follows the EU MDR.

This guide is about getting to market in Great Britain. If you want to know how the requirements themselves differ between UKCA and CE marking — software classification, approved bodies versus notified bodies, post-market surveillance, labelling — read our UKCA vs CE mark comparison for medical software.

The UK picture in November 2026 — what is law and what is planned

Post-Brexit UK medical device regulation has been a moving target. The UK Medical Devices Regulations 2002 (UK MDR 2002) gave effect in UK law to the old EU directives, and the current UKCA requirements are still based on them. CE mark acceptance has been extended repeatedly, and the wider reform has been delivered in stages. Here is where things stand:

  • CE marking recognised in Great Britain (law today): devices that comply with the EU MDR or EU IVDR can be placed on the GB market until 30 June 2030. Devices under the old EU MDD/AIMDD can be placed on the market until the sooner of certificate expiry or 30 June 2028 (IVDD devices: sooner of certificate expiry or 30 June 2030). Self-declared Class I devices have their own conditions, set out on GOV.UK.
  • Indefinite recognition (government intention, not yet law): on 21 October 2026 the government published its response to the consultation on indefinite recognition. It intends to recognise CE marked devices certified under the EU MDR and EU IVDR indefinitely, and to align the end date for MDD-certified devices with the EU transition timelines. These changes still need legislation, subject to parliamentary approval, which the government says will be made before the end of the earliest relevant transition period (30 June 2028). Until then, the dates above apply.
  • Post-market surveillance (law since 16 June 2025): strengthened GB post-market surveillance requirements apply to all devices on the GB market, including CE marked devices.
  • Pre-market regulations (planned): MHRA has said a further statutory instrument will introduce new pre-market requirements — UDI, changes to the classification of several device types, essential requirements more closely aligned with the EU, and a framework for international reliance. MHRA's implementation update (last updated March 2026) says it will follow in 2026; the October 2026 government response still describes these requirements as upcoming.
  • UKCA marking: remains available. The government response confirms the UKCA mark will remain a route to market alongside continued recognition of CE marked devices.
Northern Ireland is different: the EU MDR has applied in Northern Ireland since 26 May 2021 and the EU IVDR since 26 May 2022. CE marking is required for the Northern Ireland market (with the UKNI indication where a UK notified body performed the assessment), and the UKCA mark is not recognised there. If you sell in both GB and NI, plan for CE marking in any case.

Great Britain and Northern Ireland side by side

“The UK” is two regulatory markets for medical devices. The table summarises what changes for a software manufacturer depending on where the device is placed on the market.

Great Britain and Northern Ireland compared
Great Britain (England, Scotland, Wales)Northern Ireland
Law that appliesUK MDR 2002, as amended, including the GB post-market surveillance rules in force since 16 June 2025EU MDR since 26 May 2021 and EU IVDR since 26 May 2022
Marking acceptedUKCA, or CE marking under the recognition dates (EU MDR/IVDR devices until 30 June 2030 under current law)CE marking. CE with the UKNI indication where a UK notified body did the assessment. UKCA is not accepted
RepresentativeManufacturers based outside the UK appoint a UK Responsible PersonGB-based manufacturers designate an authorised representative in the EU or Northern Ireland; manufacturers based in Northern Ireland do not need one in the EU. Importers check that an authorised representative is designated where the manufacturer is outside Northern Ireland and the EU
RegistrationDevices registered with the MHRA before they are placed on the GB marketEUDAMED: the actor, UDI/device registration, notified body and certificate, and market surveillance modules have been mandatory since 28 May 2026. GOV.UK says GB- and NI-based actors must register in EUDAMED. Custom-made devices are still registered with the MHRA
Who certifiesUK approved bodies (UKCA) or EU notified bodies (CE)EU notified bodies, or UK notified bodies (CE UKNI)
Post-marketGB PMS rules; serious incidents reported to the MHRA within 2, 10 or 15 calendar days depending on severityEU MDR post-market surveillance and vigilance rules

Two GOV.UK pages describe Northern Ireland registration slightly differently. “Regulating medical devices in the UK” (updated 20 February 2026) says certain devices had to be registered with the MHRA until 27 May 2026. “Regulation of medical devices in Northern Ireland” (updated 11 June 2026) describes EUDAMED registration from 28 May 2026. If you place devices on the NI market, check both pages and the MHRA registration guidance for your device type.

Two routes to the GB market for software

Route 1 — CE marking under the EU MDR, recognised in GB

For most EU-first SaMD companies this is the practical route: your EU MDR certificate and CE marking are the conformity basis in GB. You still have GB-specific obligations: a UK Responsible Person if you are based outside the UK, registration of your devices with the MHRA before placing them on the GB market, and compliance with the GB post-market surveillance requirements. If you are still building your EU file, our EU MDR consulting covers the CE route these steps build on.

Route 2 — UKCA marking under UK MDR 2002

UKCA marking shows conformity with UK MDR 2002. Class I devices are self-declared (an approved body is needed only for sterile or measuring aspects); Class IIa, IIb and III devices need a UK approved body. UK approved bodies cannot carry out CE assessments, and the UKCA mark is not recognised in the EU, EEA or Northern Ireland. Because UK MDR 2002 classification follows the older directive-based rules, the UK class of your software may differ from its EU MDR class — check this in the comparison guide linked above before choosing.

Qualification and classification in the UK

Whether software qualifies as a medical device in the UK follows the same basic logic as in the EU: it depends on whether the intended purpose is a medical purpose. Classification is where the two systems can part ways, because UK MDR 2002 has no equivalent of EU MDR Rule 11. The government's 2026 consultation response itself notes that, while GB and EU classification rules are largely aligned, some differences exist. The planned pre-market regulations will change the classification of several device types; the 2026 documents name IVDs (alignment with IMDRF) and implantable devices, but do not detail changes for software — check the statutory instrument when it is laid.

MHRA software guidance to use now

  • Crafting an intended purpose for SaMD (MHRA, published 22 March 2023). It asks for an unambiguous intended purpose built from four elements: the structure and function of the device, the intended population, the intended user, and the intended use environment. It also names common problems: vague purposes, multi-purpose devices, function creep, and a purpose that the evidence does not support. The same statement drives qualification and classification in both GB and the EU, so it is worth writing once, carefully.
  • Medical devices: software applications (apps) (MHRA, page last updated 1 July 2023). It links MHRA’s guidance document on stand-alone software, including apps, for deciding whether software is a medical device and how it is classified under UK MDR 2002.
A page published in error. On 6 November 2026 a GOV.UK publication page at the address /government/publications/guidance-on-bringing-software-as-a-medical-device-to-market was replaced with the notice “This page was published in error and will be published again in due course.” We have not seen its content, and nothing in this guide is based on it. We will update this guide when the MHRA publishes it.

UKCA certification — the process for medical software

For SaMD that requires third-party assessment under UK MDR 2002 (Class IIa and above), UKCA certification requires working with a UK approved body. The process follows these steps:

  1. Determine the applicable classification under UK MDR 2002
  2. Select a UK approved body — check the current list of UK approved bodies for medical devices on GOV.UK and confirm the body's scope covers your device
  3. Prepare technical documentation against the UK MDR 2002 requirements. Companies with existing EU MDR technical files can adapt these, but the legal references and some requirements differ
  4. Undergo conformity assessment by the UK approved body; after a signed declaration of conformity, affix the UKCA mark with the approved body's number
  5. Appoint a UK Responsible Person if you are based outside the UK
  6. Register your devices with the MHRA before placing them on the GB market

UK Responsible Person and MHRA registration

Manufacturers based outside the UK must appoint a UK Responsible Person (UKRP) for the GB market and give it written evidence of its authority. The UKRP registers the manufacturer's devices with the MHRA, ensures the declaration of conformity and technical documentation have been drawn up, keeps a copy of the technical documentation available, cooperates with the MHRA on preventive or corrective action, and passes complaints and reports from healthcare professionals, patients and users to the manufacturer. An importer or distributor may act as UKRP. Where the UKCA mark is affixed, the UKRP's name and address must appear on the labelling, outer packaging or instructions for use.

All medical devices must be registered with the MHRA before being placed on the GB market — without registration, you cannot lawfully place the device on that market. A fee may be payable for new registrations and changes.

Old authorised representative accounts: accounts of former GB-based authorised representatives that had not updated their role to UK Responsible Person were suspended from 1 January 2022; if not updated by 30 March 2026, they are closed and a new account must be created. If you rely on a UKRP appointed years ago, check that its MHRA account and your device registrations are current.

Post-market surveillance in GB — in force since 16 June 2025

Strengthened post-market surveillance requirements for Great Britain came into force on 16 June 2025. They apply to devices placed on the GB market — including CE marked devices relying on recognition — and the October 2026 government response keeps them as a condition of continued CE recognition.

In practice this means a PMS process that covers GB, reporting serious incidents to the MHRA, managing field safety corrective actions with the MHRA, and complaint handling that captures GB users. Companies that previously focused only on EU MDR post-market obligations now have a parallel GB obligation to manage.

The GB vigilance time limits are set out in MHRA’s vigilance reporting guidance (regulation 44ZH). A serious public health threat must be reported no later than 2 calendar days after the manufacturer becomes aware of it. A death or unanticipated serious deterioration in health must be reported within 10 calendar days, and all other serious incidents within 15 calendar days (previously 30). Build these limits into the same complaint triage your support team uses for EU users, so a GB case is not discovered on day 14.

International reliance — what MHRA has actually said

International reliance is often described as already available. It is not. MHRA has said the planned pre-market regulations will introduce a new framework for international reliance, enabling swifter access for devices already approved by comparable regulators. The 2026 implementation update and the October 2026 government response do not list which regulators or routes will qualify, and the legislation had not been laid when the response was published. The government also decided not to create a separate reliance route for EU MDR/IVDR devices that are classed higher in GB — because it intends to recognise those CE marked devices indefinitely instead. Do not build a launch plan on reliance until the statutory instrument is published.

Strategy: how to handle GB and EU together

For SaMD companies selling in both the EU and GB, the most practical strategy today is:

  • Certify under the EU MDR (CE marking) as the primary certification — it covers the EU and EEA, Northern Ireland, and is recognised in GB until 30 June 2030 under current law
  • Appoint a UK Responsible Person, register your devices with the MHRA, and run GB post-market surveillance
  • Track the legislation implementing indefinite recognition of EU MDR/IVDR CE marking (intended before 30 June 2028) and the pre-market statutory instrument
  • Consider UKCA if your GB business depends on a route under UK control, or if your product's classification makes UKCA attractive — the UKCA mark remains available

What to do now: a checklist for SaMD manufacturers

  1. Check the intended purpose against the four elements in MHRA’s intended-purpose guidance, and use the same wording in your EU and GB documentation.
  2. Confirm qualification and the UK class under UK MDR 2002 using MHRA’s software guidance. Record where the UK class differs from your EU MDR Rule 11 class, and why.
  3. Choose the GB route: CE marking under recognition (EU MDR devices until 30 June 2030 under current law), or UKCA.
  4. If you are based outside the UK, appoint a UK Responsible Person and register your devices with the MHRA before placing them on the GB market. If your UKRP was appointed years ago, check that its MHRA account and your registrations are current.
  5. Add GB to your post-market system: GB complaints captured, MHRA as the recipient of GB serious incident reports, the 2, 10 and 15-day limits in your triage procedure, and GB in your PMS plan and reports.
  6. If you also supply Northern Ireland, treat it as an EU MDR market: CE marking, an authorised representative in the EU or Northern Ireland where required, and EUDAMED registration.
  7. Track three things: the legislation for indefinite recognition of CE marking (intended before 30 June 2028), the pre-market statutory instrument, and the republication of MHRA’s software guidance.
Official sources & references